诺德:揭示阿尔茨海默病中A和β的潜在动力学
1Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, 201 E. 24th Street, Austin, Texas 78712, USA.
概括
我们开发了一种新的数学模型,LNODE,用于跟踪阿尔茨海默病 (AD) 中的粉样β (Aβ) 进展. 这种模型显著改善了Aβ-PET数据的合适性,表明了不同的Aβ进展亚型.
科学领域:
- 神经科学是一个神经科学.
- 数学建模的数学建模
- 生物物理学的生物物理.
背景情况:
- 粉样β (Aβ) 定子发射断层扫描 (PET) 对于管理阿尔茨海默病 (AD) 是至关重要的.
- 了解Aβ进展动态对于有效的AD管理和治疗开发至关重要.
- 现有的模型可能无法完全捕捉Aβ积累和传播的复杂机制.
研究的目的:
- 介绍和评估一种新的数学模型,LNODE (潜网络普通微分方程),用于分析Aβ进化.
- 通过使用网络方法,将Aβ动态与分离的灰色物质区域相结合.
- 为了调查阿尔茨海默病中Aβ进展的潜在亚型.
主要方法:
- 开发了LNODE模型,跟踪正常的Aβ,异常的Aβ,以及灰色物质区域内的潜在状态.
- 用特定主体和队列参数对模型进行参数化.
- 通过将阿尔茨海默病神经成像倡议 (ADNI) 数据集中的585名受试者的Aβ-PET数据与Aβ-PET数据相匹配,共同逆转了模型参数.
主要成果:
- LNODE模型实现了群体R2 ≥98%,显著优于没有潜伏状态的模型 (R2 ≤60%).
- 该模型在配合Aβ-PET数据方面表现出高准确性,表明其在捕捉疾病动态方面的有效性.
- 初步发现表明,在Aβ进展模式中存在不同的亚型.
结论:
- 伦德模型为理解和量化阿尔茨海默氏病中的Aβ进展提供了一个强大的框架.
- 纳入潜态显著增强模型的能力,以表示复杂的生物过程.
- 鉴定了Aβ进展的潜在亚型,需要进一步研究个性化治疗策略.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.3K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
